RxDoctor Payments DataLook up a doctor →

Paul Hubbell, MD

Interventional Pain Medicine · Metairie, LANPI 1487685673

Payments from drug & device makers

$33,243in general payments, 2019–2025

Across 434 payments — averaging $76.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Omnia Medical, LLC$11K
  • Hydrocision, Inc.$6K
  • Medtronic$5K
  • Boston Scientific$3K
  • Vertiflex, Inc.$1K
  • Collegium Pharmaceutical, Inc.$846
  • plus $6K from 45 others
$820in research payments, 2019–2025

Across 1 payment — averaging $820.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$820

What the payments were for

  • Consulting fees$17,57853%
  • Travel & lodging$1,3354%
  • Food & beverage$14,16543%
  • Education$40%
  • Entertainment$1600%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,243 in reported general payments places this provider in the 85th percentile of 57 interventional pain medicine providers in Louisiana.

See all interventional pain medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$124,913
Medicare patients
207
Services billed
1,039

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate115$104,354
NucyntaTapentadol Hcl11$11,336
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen464$10,890
Morphine Sulfate ErMorphine Sulfate239$10,842
Tizanidine Hcl570$10,590
BelbucaBuprenorphine Hcl15$8,156
MovantikNaloxegol Oxalate19$7,960
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen261$7,417
OxycontinOxycodone Hcl12$5,379
Fentanyl33$5,158
Gabapentin312$4,823
Duloxetine Hcl338$4,272
Pregabalin157$4,258
Oxycodone Hcl151$3,019
Lidocaine20$2,790

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta, Belbuca$846$123,846141 claims
Redhill Biopharma Inc.Movantik$37$7,96019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 57 interventional pain medicine providers in Louisiana.

Other interventional pain medicine in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →